Ceritinib is a second-generation selective oral ALK inhibitor and proves to be effective in the first-line treatment for ROS1-positive NSCLC.[12,13] It is recommended in the NCCN guidelines for the treatment of ROS1-positive metastatic NSCLC, based on an open-label, multicenter, phase II study.[14] This study confirmed the effectiveness of ceritinib in ROS1-positive NSCLC patients who were not treated with crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.